

Helping people breathe better and live fuller lives.



ATS Conference 2021 Virtual Platform



Jason Suggett¹,

¹Science and Technology, Trudell Medical International, London, ON, Canada, ²Fluidda, Kontich, Belgium.

Metered Dose Inhaler (MDI) with Valved Holding Chamber (VHC) vs Dry Powder Inhalers (DPIs): Using Functional Respiratory Imaging (FRI) to Assess Modelled Lung **Deposition in an Asthmatic patient.**

Rationale


Methods

Results

V. Kushnarev¹, C. Van Holsbeke², S. Van Steen², B. Mignot²;


RATIONALE

- Both MDIs and DPIs can be used to deliver drugs to manage Asthma.
- Valved Holding Chambers (VHC) can be used to help patients with inhalation coordination of their MDIs.
- Inspiratory flow rate is known to influence drug delivery. This FRI based study assessed the modelled airway drug delivery from an MDI/VHC system and two DPI systems at optimal and sub-optimal flow rates.




HRCT

1. Patient data is obtained by taking low dose CT scans



Structure segmentation



Patient-specific 3D model

2. Patient-specific airway and lung structures are extracted

3. Flow and particle simulations are applied to the 3D models


Rationale	Methods	Results	




Flow simulation (CFD)

METHODS

- Three dimensional geometries of airways and lobes were extracted from a CT scan of a 21 year old male Asthma (moderate) patient.
- Drug delivery and airway deposition was modelled using FRI with measured particle and plume characteristics via the following devices:



AeroChamber Plus* Flow-Vu* ((AC+) valved holding chamber (VHC), Trudell Medical International) delivering salbutamol from a Ventolint EvoHalert pMDI (100 µg; GSK)



Symbicort+ Turbuhaler+ (6 µg formoterol fumarate/200 µg budesonide; AstraZeneca)

 Inhalation flowrates of 30 L/min (optimum for MDI/VHC, sub-optimal for DPIs) and 60 L/min (optimum for DPIs, sub-optimal for MDI/VHC) were assessed.

	Rationale	Methods	Results	
- 1				




Seretide[†] Diskus[†] (50 µg salmeterol xinafoate/250 µg fluticasone propionate; GSK)

RESULTS

• The modelled lung deposition results are shown in the chart below, expressed as a percentage of label dose, using both optimal and sub-optimal inhalation flow rates.


Percentage of Label Dose Delivered to Lungs





CONCLUSIONS

- The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu*VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
- The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.



Rationale	Methods	Results	

